PH12019501047A1 - Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) - Google Patents

Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Info

Publication number
PH12019501047A1
PH12019501047A1 PH12019501047A PH12019501047A PH12019501047A1 PH 12019501047 A1 PH12019501047 A1 PH 12019501047A1 PH 12019501047 A PH12019501047 A PH 12019501047A PH 12019501047 A PH12019501047 A PH 12019501047A PH 12019501047 A1 PH12019501047 A1 PH 12019501047A1
Authority
PH
Philippines
Prior art keywords
nafld
nash
reversal
extended
treatment
Prior art date
Application number
PH12019501047A
Other languages
English (en)
Inventor
Borunda Juan Socorro Armendariz
Castro Jos‚ Agust¡N Rogelio Maga¥A
Aldana Nadiel Hernandez
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Publication of PH12019501047A1 publication Critical patent/PH12019501047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12019501047A 2016-11-11 2019-05-10 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) PH12019501047A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Publications (1)

Publication Number Publication Date
PH12019501047A1 true PH12019501047A1 (en) 2019-12-11

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501047A PH12019501047A1 (en) 2016-11-11 2019-05-10 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (3) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
CN111386115A (zh) * 2017-11-28 2020-07-07 艾格尔峰生物制药有限公司 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN116159056A (zh) * 2023-03-09 2023-05-26 中南大学湘雅医院 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
JOP20190102A1 (ar) 2019-05-06
ZA201903012B (en) 2020-09-30
CA3043300A1 (en) 2018-05-17
AU2024200737A1 (en) 2024-02-22
MX2016014775A (es) 2018-05-10
RU2019116422A3 (enExample) 2021-04-09
JP2019535822A (ja) 2019-12-12
CO2019004799A2 (es) 2019-07-31
MA45754A1 (fr) 2019-12-31
AR110057A1 (es) 2019-02-20
PE20191149A1 (es) 2019-09-02
US20250325530A1 (en) 2025-10-23
AU2017358367B2 (en) 2023-11-09
CN110248646A (zh) 2019-09-17
RU2019116422A (ru) 2020-12-11
KR20190084056A (ko) 2019-07-15
ECSP19031851A (es) 2019-06-30
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX364040B (es) 2019-04-11
CN115969802A (zh) 2023-04-18
US20230181550A1 (en) 2023-06-15
JP2022173344A (ja) 2022-11-18
IL266519A (en) 2019-07-31
CL2019001280A1 (es) 2019-07-19
WO2018088886A1 (es) 2018-05-17
AU2026200298A1 (en) 2026-02-05
US20190262325A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JOP20190102A1 (ar) استخدام صيدلي لتركيب له إطلاق ممتد يحتوي على بيرفنيدون من أجل علاج والتعافي من التهاب الكبد الدهني البشري ((داء الكبد الدهني غير الكحولي nafld)/التهاب الكبد الدهني غير الكحولي nash))
JOP20200137A1 (ar) نظائر إنكريتين واستخداماتها
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
IN2015DN00376A (enExample)
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MX367132B (es) Nueva cepa de bifidobacterium animalis subsp. lactis cect 8145 y su uso para el tratamiento y/o prevencion de sobrepeso y obesidad y enfermedades asociadas.
Adler et al. Glucocorticoid-induced osteoporosis
NZ799031A (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
IL272457A (en) GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis
MY188344A (en) Extract formulations of rhodamnia cinerea and uses thereof
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
EP3661600A4 (en) FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
EP3316874A4 (en) TOPICAL AND INJECTABLE RESIQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC GUM DISEASES
MX2018004489A (es) Extracto de agavaceae que comprende saponinas esteroidales y su uso para tratar y/o prevenir patologías relacionadas con desórdenes metabólicos.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
PH12016501548A1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
IL281404A (en) A traditional Chinese medicine compound for treatment
Celis et al. Obesity and inflammation. The effect of Resveratrol
Ha et al. Chloroform Fraction Of Gleditsia Sinensis Thorns Activates Nrf2 And Increases The Expression Of Antioxidant Genes
NZ748511A (en) Method maintaining iron homeostasis with shogaols
Schmidt et al. Stress-induced local inflammation correlates with an increase in inflammatory myeloid cells